These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 6124987)

  • 1. [The role of high-dosage neuroleptic therapy and electroshock in the treatment of the acute phase of schizophrenia].
    Ungvári G; Bitter I; Czobor P; Vitrai J; Pethö B
    Psychiatr Neurol Med Psychol (Leipz); 1981 Aug; 33(8):458-63. PubMed ID: 6124987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aripiprazole: new drug. Just another neuroleptic.
    Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rabbit syndrome and tardive dyskinesia: two complications of chronic neuroleptic treatment.
    Schwartz M; Weller B; Erdreich M; Sharf B
    J Clin Psychiatry; 1995 May; 56(5):212. PubMed ID: 7737962
    [No Abstract]   [Full Text] [Related]  

  • 6. The influence of concomitant neuroleptic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy.
    Nothdurfter C; Eser D; Schüle C; Zwanzger P; Marcuse A; Noack I; Möller HJ; Rupprecht R; Baghai TC
    World J Biol Psychiatry; 2006; 7(3):162-70. PubMed ID: 16861142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of higher-dose haloperidol therapy with perazine standard therapy in acute schizophrenic patients].
    Schmidt LG; Schüssler G; Kappes CV; Müller-Oerlinghausen B
    Nervenarzt; 1982 Sep; 53(9):530-6. PubMed ID: 6127637
    [No Abstract]   [Full Text] [Related]  

  • 8. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 9. [Long-term therapy of chronic schizophrenic patients with haloperidol decanoate].
    Roncoroni D
    Psychiatr Prax; 1984 Mar; 11(2):56-8. PubMed ID: 6144121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
    Cesková E; Svestka J
    Pharmacopsychiatry; 1993 Jul; 26(4):121-4. PubMed ID: 7694306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rapid and megadose neuroleptic therapy. Critical review].
    de Girolamo G
    Minerva Psichiatr; 1985; 26(4):323-6. PubMed ID: 2869395
    [No Abstract]   [Full Text] [Related]  

  • 12. Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis.
    Singh MM; Kay SR
    Biol Psychiatry; 1979 Apr; 14(2):277-94. PubMed ID: 38865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects.
    Kinon BJ; Kane JM; Chakos M; Munne R
    Psychopharmacol Bull; 1993; 29(3):365-9. PubMed ID: 7907184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of neuroleptic-induced parkinsonism in psychotic patients receiving adjunctive electroconvulsive therapy.
    Mukherjee S; Debsikdar V
    Convuls Ther; 1994 Mar; 10(1):53-8. PubMed ID: 7914462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuation ECT in treatment-resistant schizophrenia: a controlled study.
    Chanpattana W; Chakrabhand ML; Sackeim HA; Kitaroonchai W; Kongsakon R; Techakasem P; Buppanharun W; Tuntirungsee Y; Kirdcharoen N
    J ECT; 1999 Sep; 15(3):178-92. PubMed ID: 10492856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haloperidol decanoate in the treatment of schizophrenia.
    Zapletálek M; Zbytovský J
    Act Nerv Super (Praha); 1989 Apr; 31(1):39-41. PubMed ID: 2571224
    [No Abstract]   [Full Text] [Related]  

  • 17. Continuation electroconvulsive therapy for relapse prevention in middle-aged and elderly patients with intractable catatonic schizophrenia.
    Suzuki K; Awata S; Takano T; Ebina Y; Iwasaki H; Matsuoka H
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):481-9. PubMed ID: 16048455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group.
    Daniel DG; Wozniak P; Mack RJ; McCarthy BG
    Psychopharmacol Bull; 1998; 34(1):61-9. PubMed ID: 9564200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A differential approach to the improvement of prevention and correction of neuroleptic side extrapyramidal disorders with pantogam activ in patients with schizophrenia].
    Tiganov AS; Panteleeva GP; Abramova LI; Bologov PV; Kananovich PS; Omel'chenko MA; Nikiforova IY
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2):72-80. PubMed ID: 28374697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open study with bromperidol (C-C 2489), a new neuroleptic, for the determination of the neuroleptic threshold and the neuroleptic-therapeutic range.
    Haase HJ; Kaumeier S; Schwarz H; Gundel A; Linde OK; Maetz H; Scheel R; Stripf A; Stripf L
    Pharmakopsychiatr Neuropsychopharmakol; 1978 Mar; 11(2):81-5. PubMed ID: 643910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.